Suggested remit: To appraise the clinical and cost effectiveness of ritlecitinib within its marketing authorisation for severe alopecia areata in people 12 years and over.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process TA
ID number 4007

Provisional Schedule

Final draft guidance 22 February 2024 - 07 March 2024
Expected publication 27 March 2024

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Stakeholders

Companies sponsors Pfizer
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Alopecia UK
Professional groups British Association of Dermatologists
  Royal College of Physicians
General commentators All Wales Therapeutics and Toxicology Centre
  Board of Community Health Councils in Wales
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Medicines and Healthcare products Regulatory Agency
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
16 January 2024 Committee meeting: 2
24 November 2023 - 15 December 2023 Draft guidance
05 September 2023 Committee meeting: 1
10 February 2023 The appraisal committee meeting will now take place on 5 September 2023.
25 October 2022 Invitation to participate
13 September 2022 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of ritlecitinib for treating moderate to severe alopecia areata in people 12 years and over. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during mid-October 2022. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
12 May 2022 - 13 June 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
28 January 2022 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual